Combined chloroquine/Fansidar-resistant falciparum malaria appears in East Africa.
The first two cases from East Africa of RII chloroquine- and Fansidar-resistant falciparum malaria are described. The first case occurred in a non-immune Swedish expatriate 2 weeks after arrival in Tanzania, and the second in a semi-immune Tanzanian soldier. Fansidar has not yet been marketed in Tanzania. The significance and etiology of the occurrence of combined chloroquine/Fansidar resistance in East Africa are discussed.
D000328:Adult; D000962:Antimalarials / Q000494:pharmacology*; D002738:Chloroquine / Q000494:pharmacology / Q000627:therapeutic use*; D004338:Drug Combinations / Q000494:pharmacology / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010963:Plasmodium falciparum / Q000187:drug effects; D011739:Pyrimethamine / Q000494:pharmacology / Q000627:therapeutic use*; D013413:Sulfadoxine / Q000494:pharmacology / Q000627:therapeutic use*; D013424:Sulfanilamides / Q000627:therapeutic use*; D013636:Tanzania
D000962:Antimalarials; D004338:Drug Combinations; D013424:Sulfanilamides; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D002738:Chloroquine; D011739:Pyrimethamine